MorphoSys
Planegg · Founded 1992
About MorphoSys
MorphoSys AG is a biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Boehringer Ingelheim, Daiichi Sankyo, Merck & Co, Novartis, Pfizer, and Roche.
Company Facts
- Founded: 1992
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $100K – $500K
- Total funding: $748.1M
- Funding stage: M&A
- Last round: Post-IPO Equity (Dec 2023)
- Ticker: etr:MOR
- Website: morphosys.com
- Phone: +49 89 899270
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical
Social Profiles
Canonical: https://fsome.com/organization/morphosys-95548 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.